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Abstract 
Introduction:  Dietary nitrate (NO3
-
) supplementation, via its reduction to
 
nitrite (NO2
-
) 
and subsequent conversion to nitric oxide (NO) and other reactive nitrogen intermediates, 
reduces blood pressure and the O2 cost of submaximal exercise in humans. Despite these 
observations, the effects of dietary NO3
-
 supplementation on skeletal muscle vascular control 
during locomotory exercise remain unknown.  We tested the hypotheses that dietary NO3
-
 
supplementation via beetroot juice (BR) would reduce mean arterial pressure (MAP) and 
increase hindlimb muscle blood flow in the exercising rat.  Methods:  Male Sprague-Dawley 
rats (3-6 months) were administered either NO3
-
 (via beetroot juice; 1 mmol · kg
-1
 · day
-1
, BR 
n=8) or untreated (control, n=11) tap water for 5 days. MAP and hindlimb skeletal muscle blood 
flow and vascular conductance (radiolabeled microsphere infusions) were measured during 
submaximal treadmill running (20 m · min
-1
, 5% grade). Results:  BR resulted in significantly 
lower exercising MAP (control: 137 ± 3, BR: 127 ± 4 mmHg, P<0.05) and blood [lactate] 
(control: 2.6 ± 0.3, BR: 1.9 ± 0.2 mM, P<0.05) compared to control. Total exercising hindlimb 
skeletal muscle blood flow (control: 108 ± 8, BR: 150 ± 11 ml · min
-1
 · 100 g
-1
, P<0.05) and 
vascular conductance (control: 0.78 ± 0.05, BR: 1.16 ± 0.10 ml · min
-1
 · 100 g
-1
 · mmHg
-1
, 
P<0.05) were greater in rats that received beetroot juice compared to control. The relative 
differences in blood flow and vascular conductance for the 28 individual hindlimb muscles and 
muscle parts correlated positively with their percent type IIb + d/x muscle fibers (blood flow: 
r=0.74, vascular conductance: r=0.71, P<0.01 for both). Conclusion:  These data support the 
hypothesis that NO3
-
 supplementation improves vascular control and elevates skeletal muscle O2 
delivery during exercise predominantly in fast-twitch type II muscles, and provide a potential 
mechanism by which NO3
-
 supplementation improves metabolic control. 
 
iv 
 
 
Table of Contents 
List of Figures ........................................................................................................................................ vi 
List of Tables ......................................................................................................................................... vii 
Abbreviations Used ........................................................................................................................... viii 
Dedication ............................................................................................................................................... ix 
Chapter 1 - Introduction ..................................................................................................................... 1 
Chapter 2 - Literature Review........................................................................................................... 3 
Vasoactive properties of NO2- ............................................................................................................................. 4 
Dietary sources of NO3- and NO2- ....................................................................................................................... 5 
NO3- supplementation and muscle metabolic and contractile function ..................................................... 6 
NO3- and O2 uptake ............................................................................................................................................... 6 
Chapter 3 - Methods ............................................................................................................................. 8 
Ethical approval ................................................................................................................................................... 8 
BR Supplementation ............................................................................................................................................ 8 
Instrumentation and regional BF measurements .......................................................................................... 8 
Determination of regional BF and VC .............................................................................................................. 9 
Blood sampling and measurement of Plasma NO3- and NO2- .................................................................... 10 
Statistical analysis ............................................................................................................................................ 10 
Chapter 4 - Results .............................................................................................................................. 12 
Effects of BR on plasma [NO3-] and [NO2-] .................................................................................................... 12 
Effects of BR on HR, MAP, and blood [lactate] at rest and during exercise ............................................ 12 
Effects of BR on skeletal muscle BF and VC at rest and during exercise ................................................. 12 
Effects of BR on renal and splanchnic BF and VC at rest and during exercise ....................................... 13 
Chapter 5 - Discussion ....................................................................................................................... 14 
Effects of BR on plasma [NO3-], [NO2-] and MAP .......................................................................................... 14 
Effects of BR on exercising inter- and intra-muscular hindlimb BF and VC ........................................... 14 
Experimental considerations and future directions ................................................................................... 17 
Conclusions ......................................................................................................................................................... 17 
v 
 
References ........................................................................................................................................................ 28 
 
  
vi 
 
List of Figures 
 
Figure 1.  ........................................................................................................................................24 
Figure 2. .........................................................................................................................................25 
Figure 3.  ........................................................................................................................................26 
Figure 4. .........................................................................................................................................27 
  
vii 
 
List of Tables 
Table 1. Effects of 5 days of BR supplementation on HR, MAP, and blood [lactate] at rest and 
during exercise. ..................................................................................................................... 19 
Table 2. Effects of BR supplementation on resting hindlimb muscle BF (ml · min-1 · 100 g-1) 
and VC (ml · min-1 · 100 g-1 · mmHg-1). ............................................................................ 20 
Table 3. Effects of BR supplementation on exercising hindlimb muscle BF (ml · min-1 · 100 g-1) 
and VC (ml · min-1 · 100 g-1 · mmHg-1). ............................................................................. 21 
Table 4. Effects of BR supplementation on BF (ml · min
-1
 · 100 g
-1
) and VC (ml · min
-1
 · 100 g
-1
 · 
mmHg
-1
) to the kidneys and organs of the splanchnic region measured at rest and during 
exercise. ................................................................................................................................ 23 
 
  
viii 
 
Abbreviations Used 
 
NO, nitric oxide; NOS, nitric oxide synthase; eNOS, endothelial nitric oxide synthase; 
nNOS, neuronal nitric oxide synthase; iNOS, inducible nitric oxide synthase; NO3
-
, nitrate; NO2
-
, 
nitrite; BR, beetroot juice; HR, heart rate; MAP, mean arterial pressure; VC, vascular 
conductance; , oxygen uptake; BF, blood flow; PO2mv, microvascular partial pressure of 
oxygen; PCr, phosphocreatine.  
  
2OV

ix 
 
Dedication 
I would like to dedicate this thesis to my mother and father who have loved and 
supported me through all of my endeavors. Mom, you have always been there for me and have 
taught me the importance of family. I have always been able to count on you for inspiration and 
strength, even through the toughest of days. Dad, thanks for instilling the importance of 
education in me. You have always set a perfect example for us kids to follow and I intend to 
always honor the values and lessons you have taught me. I thank God that I have been blessed 
with a great family and look forward to surrounding my children with the love and fortitude you 
have shown me. Thanks for all you do! 
 
 
Love always
1 
 
 
Chapter 1 - Introduction 
It is now recognized that NO functions as a major contributor to skeletal muscle vascular 
and metabolic control (reviewed by Joyner & Tschakovsky, 2003).  NO is produced 
endogenously by the reduction of L-arginine to L-citrulline via three distinct NOS isoforms: 
constitutively expressed eNOS and nNOS, as well as iNOS (reviewed by Stamler & Meissner, 
2001).  In addition, there is emerging evidence that dietary inorganic NO3
-
 delivered, for 
example, via ingested BR, can be reduced to NO2
-
 and, subsequently, NO and other reactive 
nitrogen intermediates and impact hemodynamic and muscle metabolic function (Larsen et al. 
2007; Bailey et al. 2009).  These effects have been divorced from other active BR constituents 
(i.e., antioxidants; Lansley et al. 2011) and, crucially, the reduction of NO2
-
 to NO is potentiated 
by hypoxic and acidic conditions (Cosby et al. 2003), which may be present during muscular 
exercise.  In contrast, hypoxic conditions impair NOS function and therefore compromise NO 
bioavailability from that pathway under the very conditions when NO is requisite to balance O2 
delivery-to-O2 utilization in skeletal muscle (Ferreira et al. 2006ab; Hirai et al. 2010). 
In humans, acute (2-3 hours) and chronic (3-6 days) dietary NO3
-
 ingestion via sodium 
NO3
-
 salt (Larsen et al. 2007) or BR (Bailey et al. 2009; Vanhatalo et al. 2010a; Kenjale et al. 
2011; Lansley et al. 2011) reduces blood pressure, lowers submaximal exercise , and has 
been shown to enhance exercise tolerance.  In addition, BR ameliorates the muscle metabolic 
perturbations found during exercise when breathing a hypoxic inspirate (Vanhatalo et al. 2011), 
improves muscle oxygenation in peripheral artery disease patients (Kenjale et al. 2011), and 
improves human mitochondrial efficiency as measured using the P/O ratio (Larsen et al. 2011). 
Collectively, these investigations suggest that augmented dietary NO3
-
 might serve to 
maintain or even increase skeletal muscle BF (and hence O2 delivery) in the presence of reduced 
O2 demand, which may be expected to enhance metabolic control via increases in intramyocyte 
PO2. However, we are unaware of any measurements of BF and VC within and among skeletal 
muscles during locomotory exercise. Indeed, within the running rat model it is possible to 
determine the impact of BR on vascular control across discrete muscle fibre type populations.  
Such information is essential for resolving the effect of BR on O2 delivery-to-O2 utilization 
matching within and across muscles, which may have important metabolic consequences.  
2OV
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Accordingly, the purpose of the present investigation was to test the hypotheses that ingesting 
BR for 5 days would, in the face of increased plasma [NO3
-
], [NO2
-
], and lowered MAP: 1) 
increase BF and VC in locomotory muscles across the spectrum of both high and low oxidative 
capacities, and 2) and thereby presumably increase the O2 delivery-to-O2 utilization ratio thus 
reducing blood [lactate].  Results from the present investigation may provide mechanistic links 
between changes in plasma [NO3
-
] and [NO2
-
] and improved muscle oxygenation and metabolic 
function following NO3
-
 supplementation (Kenjale et al. 2011; Vanhatalo et al. 2011). 
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Chapter 2 - Literature Review 
Less than 10 years after Furchgott and Zawadski’s seminal discovery, work done in 
Salvador Moncada’s laboratory revealed that an enzyme known as nitric oxide synthase (NOS) 
was responsible for NO synthesis via oxidation of the amino acid L-Arginine (Moncada & 
Higgs, 1993). Since its discovery, NO has been implicated in a multitude of physiological 
processes including blood flow regulation, cellular respiration, glucose homeostasis, and muscle 
contraction (reviewed by Joyner & Tschakovsky, 2003). By the mid 1990’s a surge of 
investigations were uncovering the mechanisms by which NO elicits its cell signaling 
capabilities and the importance of this powerful biological messenger were beginning to come 
into focus.  However, as the literature progressed it became evident that, because of its high 
reactivity, NO becomes oxidized very quickly. With its short half-life it seemed that local NO 
production was obligatory to avoid the “scavenging” effects of oxygenated hemoglobin (Hb).  
 Until recently, NO was thought to be synthesized primarily by the NOS family of 
enzymes, however Zweier and colleagues (1995) used paramagnetic resonance spectroscopy 
(EPR) to show an elevated rate of NO synthesis in ischemic rat hearts despite infusion of the 
comprehensive NOS blocker n-nitro-l-arginine methyl ester (L-NAME). They concluded that 
high tissue levels of nitrite were responsible and postulated that the acidotic and low 
intravascular PO2 levels present during ischemia catalyzed the reduction of NO2
-
 into NO3
-
. This 
was the first investigation to suggest NO2
-
 as a potential NO storage pool capable of eliciting a 
cardioprotective role against tissue ischemia.   
 
NO2
-
 and NO  
For years, NO2
-
 has been used as a meat preservative to prevent botulism (Lundberg & 
Weitzberg, 1995) and, until recently, was once believed to be an inert byproduct of NO 
oxidation, offering little physiological significance. Interestingly Furchgott & Bhadrakom (1953) 
used acidified pharmacological sodium nitrite (NaNO2
-
) to induce aortic strip vasodilation 
leading to the discovery of NO’s power as endothelial derived relaxing factor (EDRF) in 1980 . 
Although the experimental conditions were far outside physiological ranges (i.e. a high dose of 
NO2
-
 was used), the demonstration of the vasoactive properties was evident. By 1990, Classen et 
al. (1990) had shown that NO2
-
 reduced blood pressure when given orally to spontaneously 
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hypertensive rats alluding to a systemic effect of NO2
-
 and further suggesting NO forming 
properties. Classen and his colleagues also questioned the role of NO3
-
 in NO2
-
 mediated NO 
production which proved to be very insightful in the years to come. The questions that remained 
were how NO2
-
 was being reduced to NO in vivo, if the reduction was physiologically relevant, 
and what role NO3
-
 played? 
 Interestingly, NO2
-
 reduction to NO is potentiated in environments of reduced pH such 
that is found in the human stomach. This was eloquently demonstrated by Lundberg et al. (1994) 
who reported that expelled gastric air from burping contained high levels (800-6000 ppb) of NO 
gas. Furthermore, expelled NO levels were increased following a meal of lettuce, which is 
known to contain high levels of NO3
-
 adding to the idea that NO3
-
 can be reduced to NO2
-
 and 
further to NO in vivo. It is noteworthy to mention that the amount of exhaled NO was attenuated 
95% after the proton pump inhibitor omeprazole was administered further substantiating that 
NO2
-
 reduction is potentiated in acidic conditions. This was one of the first reports showing the 
potential for NO2
-
 to act as a substrate for enzyme independent NO generation. However, 
whether this pathway served any role in vascular or metabolic function remained to be answered.  
 Vasoactive properties of NO2
-
 
 
 Modin et al. (2001) was perhaps the first to show the vasoactive properties of NO2
-
 (at 
physiologically relevant concentrations) using an isolated vessel preparation. In their experiment, 
vasoconstriction was induced using phenylephrine while aortic smooth muscle contractions were 
monitored to assess the speed at which the smooth muscle relaxed as the concentration of NO2
-
 
was progressively increased. This evidence unveiled the potential of NO2
- 
to augment blood flow 
in areas of reduced pH possible during ischemia and transitions in metabolic demand. 
 In addition, the reduction of NO2
-
 to NO is exacerbated in hypoxic environments, which 
may be present during muscular exercise. This was demonstrated by Cosby et al. (2003) who 
demonstrated an increase in forearm blood flow in response to infused NO2
-
 while 
simultaneously showing an atrial-venous gradient in which plasma NO2
-
 concentration was 
reduced in the venous circulation. Importantly, the improvements in blood flow were inversely 
related to Hb O2 saturation providing evidence that NO2
-
 impacts hypoxic vasodilation. 
Accounting for these data, it is now evident that NO2
-
 reduction to NO compliments NOS, and 
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thus helps maintain NO bioavailability in hypoxic environments where NOS function is 
compromised. 
Xanthine oxidoreductase (XO) has been suggested to facilitate NO2
- 
reduction and may 
protect against ischemia reperfusion injury. Located in the blood, XO is a complex flavoprotein 
enzyme that has the potential to generate reactive oxygen species such as superoxide and 
hydrogen peroxide. (McCord, 1985). Moreover, it has also been shown that XO can produce NO 
by reduction of NO2
-
 (Samouilov & Zweier, 2003). This helps to ameliorate post ischemic injury 
(i.e. infarct size) by providing additional NO to serve as a cardioprotective shield against free 
radicals and the anoxic environment as demonstrated by Webb et al. (2004) in the perfused 
ischemic rat heart. However, it is important to mention that NO synthesis via XO and NOS is 
subject to change based on substrate availability and oxygenation status of the surrounding 
tissue. More specifically, when NO2
-
 availability is limited there is a tendency for XO to generate 
damaging superoxides in lieu of NO. This is similar to NOS in which a reduced availability of L-
arginine or O2 causes an elevated generation of superoxides due to substrate scarcity. Should 
these conditions arise, there is potential for formation of the peroxynitrite radial which has been 
shown to be damaging to the endothelium (Beckman et al. 1990). Given this information, with 
an adequate supply of circulating NO2
-
, it is conceivable to render the NO3
-
- NO2
-
-NO pathway 
(regardless of the mode of NO2
- 
reduction) as a complimentary backup for anoxic situations in 
which NO production from NOS is compromised. 
 Dietary sources of NO3
-
 and NO2
- 
 
With plasma concentration of NO2
-
 of paramount importance, many physiologists have 
now focused their attention towards exogenous sources. The primary source of NO2
-
, aside from 
the endogenous oxidation of NO described earlier, is from the reduction of the closely related 
NO3
- 
anion. While mammals do not posses the enzymes required for NO3
- 
reduction, many 
bacteria possess powerful NO3
- 
 reductase enzymes enabling them to convert NO3
- 
to NO2
- 
 in 
anaerobic environments. These facultative bacteria are located in large numbers within the oral 
cavity and without them NO3
-
 reduction cannot occur (Weitzberg & Lundberg, 1998; Lundberg 
& Govoni, 2004; Lundberg et al. 2004).  
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For mammals 60-80% of the daily NO3
-
 intake is through dietary ingestion of dark green 
leafy vegetables and their roots (i.e. spinach, carrots, beetroot) (Ysart et al. 1999).  Upon 
consumption, NO3
-
 is absorbed in the gut quickly elevating plasma levels. The salivary glands 
then actively take up and secrete NO3
-
 in saliva; increasing oral levels nearly 10 fold (Duncan et 
al. 1995). NO3
-
 is then reduced to NO2
-
 and is swallowed where it is reduced to NO in the 
digestive tract or re-absorbed into the bloodstream peaking plasma NO2
-
 concentrations within 3 
hours of ingestion (Dejam et al. 2004). 
 NO3
-
 supplementation and muscle metabolic and contractile function 
 
 Aside from the vasoactive components, there is data to suggest that the dietary NO3
-
 
consumption alters muscle metabolic and contractile efficiency (Lundberg et al. 2004; 
Hernandez et al. 2012). Elevating NO bioavailability reduces mitochondrial  as NO inhibits 
cytochrome C oxidase activity by competing with O2 thereby reducing overall mitochondrial 
respiration (Brown & Cooper, 1994). In addition, recent studies suggests that both NO2
-
 and NO 
serve to increase oxidative phosphorylation efficiency by either reducing proton slippage of the 
mitochondrial proton pumps or by serving as an alternative terminal electron acceptor, 
theoretically substituting for O2 (Clerc et al. 2007; Basu et al. 2008). Collectively, these 
improvements in oxidative ATP resynthesis may provide a mechanistic linkage to increased 
plasma nitrite and reduced whole body exercising  (Larsen et al. 2007; Bailey et al. 2009; 
Vanhatalo et al. 2010a; Kenjale et al. 2011; Lansley et al. 2011).  
 NO3
-
 and O2 uptake 
 
  Larsen et al. (2007) used pharmacological NaNO3
-
 as a dietary supplement for 6 days 
and reported a reduction in submaximal  of cycling at 45-80% of max.  This was 
accomplished without an increase in glycolytic energy production as confirmed by unchanged 
blood lactate levels. Bailey et al. (2009) took this concept yet another step by supplementing 
NO3
-
-rich beetroot juice (BR) in place of the sodium NO3
-
 salt to see if the metabolic effects 
could be elicited via dietary supplementation. Three days of supplementation reduced 
submaximal  by 19% while simultaneously increasing time to exhaustion. Interestingly, the 
2OV

2OV

2OV

2OV

2OV

7 
 
 slow component was also reduced suggesting that NO3
-
 ingestion may increase exercise 
tolerance, which carries many implications for various diseases states where exercise capacity is 
reduced (i.e. heart failure, reviewed by Poole et al. 2010). In addition to the remarkable 
metabolic findings, systemic blood pressure was reduced significantly in those in the BR group 
with others reporting similar results (Gladwin et al. 2000; Larsen et al. 2007; Kenjale et al. 2011; 
Lansley et al. 2011a,b; Vanhatalo et al. 2011). Given that blood flow is mediated in part by 
vasodilatory mechanisms, it is possible that NO3
-
 supplementation may also elevate exercising 
vascular conductance manifested by a reduced driving pressure but maintained (or slightly 
elevated) blood flow.  
Of late, a barrage of studies on the effects of dietary NO3
-
 supplementation has taken 
shape investigating the possibility of augmented exercise performance, amelioration of certain 
chronic disease symptoms, and elevated tolerance to hypoxic environments. While the exact 
mechanisms of the NO3
-
-NO2
-
-NO pathway are not yet fully understood, it is quite clear that the 
relatively stable anions NO3
-
 and NO2
-
 are far from inert as once thought. The studies discussed 
in this review have helped further illuminate the role and potential benefits of NO3
-
 and NO2
-
 in 
NO bioavailability and cellular function and have paved the road for future investigations. 
  
2OV
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Chapter 3 - Methods 
  Ethical approval 
A total of 19 young adult male Sprague-Dawley rats (3-4 months old; body mass=416 ± 
12 g) were used in the present investigation. Rats were maintained on a 12:12 hr light-dark cycle 
with food and water available ad libitum. All experimental procedures were conducted under the 
guidelines established by The Journal of Physiology (Drummond, 2009) and approved by the 
Institutional Animal Care and Use Committee of Kansas State University. All rats were 
familiarized with running on a custom-built motor-driven treadmill for 5 min · day-1 at a speed of 
20 m · min-1 up a 5% grade for ~5 days. 
 
 BR Supplementation  
Rats were assigned randomly to receive either tap water (control; n=11) or 5 days of BR 
supplementation (BR; n=8) (  dose; 1 mmol · kg-1 · day-1 diluted in 100 ml of tap water; Beet 
it™, James White Drinks, Ipswich, UK) with consumption monitored daily. Preliminary studies 
in our laboratory demonstrated this dose elevated plasma [NO3
-
] and [NO2
-
] to levels 
approximating those seen in humans following NO3
-
 supplementation (Lundberg et al. 2004; 
Bailey et al. 2009; Kenjale et al. 2011). Moreover, this dose compares closely to NO3
-
 doses 
administered to humans after accounting for the ~7x greater resting metabolic rate in rats 
compared to humans (Musch et al. 1988). 
 
 Instrumentation and regional BF measurements 
Rats were first anesthetized using a 5% isoflurane-O2 mixture. Subsequently, while 
maintained on a 2-3% isoflurane-O2 mixture, a catheter (PE-10 connected to PE-50; Clay Adams 
Brand, Sparks, MD, USA) was placed in the ascending aorta via the right carotid artery. A 
second catheter (PE-10 connected to PE-50) was placed surgically in the caudal (tail) artery as 
described previously (Musch et al. 1992). Both catheters were tunneled subcutaneously to the 
dorsal aspect of the cervical region and exteriorized through a puncture wound in the skin.  
Following incision closure, anesthesia was terminated and the animal was given 1-2 hours to 
recover before initiation of the final experimental protocol (Flaim et al. 1984). 
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After recovery, the rat was placed on the treadmill and the caudal artery catheter was 
connected to a 1 ml syringe chambered in a Harvard infusion/withdrawal pump (model 907, 
Cambridge, MA, USA). The carotid artery catheter was then connected to a pressure transducer 
(Gould Statham P23ID, Valley View, OH, USA) maintained at the same height as the animal and 
exercise was initiated. Treadmill speed was increased progressively over a ~30 s period to a 
speed of 20 m · min-1 (5% grade, ~60%  max; Musch et al. 1988). The rat continued to 
exercise for another 2.5 min until a total time of 3 min was reached. At the 3 min mark the pump 
connected to the caudal artery catheter was activated and withdrawal was initiated at a rate of 
0.25 ml · min-1. Simultaneously, HR and MAP were measured and recorded using the carotid 
artery catheter.  The carotid artery catheter was then disconnected from the pressure transducer 
and 0.5-0.6 × 10
6
 15 μm diameter radiolabeled microspheres (57Co or 85Sr in random order; 
Perkin Elmer, Waltham, MA, USA)
 
were injected into the aortic arch for determination of 
regional BF. Following the microsphere injection ~0.2 ml of blood was sampled from the carotid 
artery catheter for the determination of [lactate] (Nova Stat Profile M, Nova Biomedical, 
Waltham, MA, USA) after which exercise was terminated. Following a minimum 1 hr recovery 
period, a second microsphere injection was performed while the rat sat quietly on the treadmill 
for the determination of resting BF, HR and MAP. This experimental strategy (i.e. exercise 
before rest) mitigates potential influences of the pre-exercise anticipatory response on resting 
skeletal muscle BF measurements (Armstrong et al. 1989). 
 
 Determination of regional BF and VC 
Following the second microsphere infusion, rats were euthanized with a sodium 
pentobarbital overdose (≥50 mg  · kg-1, infused into the carotid artery catheter). The thorax was 
opened and placement of the carotid artery catheter was confirmed before the internal organs and 
individual muscles and muscle parts of the hindlimb were identified and excised. Upon removal, 
tissues were weighed and placed promptly into counting vials. 
Radioactivity of each tissue was determined with a gamma scintillation counter (Packard 
Auto Gamma Spectrometer, model 5230, Downers Grove, IL, USA). Tissue BF was then 
calculated using the reference sample method (Musch & Terrell, 1992) and expressed as ml · 
VO2
10 
 
min-1 · 100 g-1. Adequate mixing of the microspheres was verified for each rat, demonstrated by 
a <15% difference in BF to the right and left kidneys and to the right and left hindlimb 
musculature. VC was calculated by normalizing BF to MAP and expressed as ml  min
-1 
 100 
g
-1 · mmHg-1. 
 
 Blood sampling and measurement of Plasma NO3
-
 and NO2
-
  
A blood sample was collected from control and BR group rats to assess differences in 
plasma [NO3
-
] and [NO2
-
]. Following instrumentation and before regional BF measurements 
~0.8 ml of blood was drawn from the caudal artery catheter and centrifuged at 5000 g at 4°C for 
6 minutes. Plasma was subsequently extracted and immediately frozen at -80 °C for later 
analysis of [NO3
-
] and [NO2
-
]. 
All measurements of plasma NO3
-
 and NO2
-
 were performed within 30 min of thawing 
via chemiluminescence with an Ionic/Sievers NO analyzer (NOA 280i, Sievers Instruments, 
Boulder, CO, USA). In order to obtain plasma NO2
-
 levels and to avoid potential reduction of 
NO3
-
, potassium iodide in acetic acid was used as a reductant. This reductant possesses the 
ability to reduce NO2
-
 to NO but is incapable of reducing higher oxides of nitrogen (i.e., NO3
-
) 
thus increasing the specificity for NO2
-
. Plasma NO3
-
 concentrations were then obtained using 
the same apparatus with the stronger reductant vanadium chloride in hydrochloric acid at a 
temperature of 95°C. This stronger reductant reduces the sum of all nitrogen oxides with an 
oxidation state of +2 or higher (predominantly NO3
-
 [µM]) but also includes NO2
-
 and 
nitrosothiols [nM]. 
 
 Statistical analysis 
Plasma [NO3
-
] and [NO2
-] were compared using unpaired Student’s t-tests. All other data 
were compared within (rest vs. exercise) and among (control vs. BR) groups using mixed 2-way 
ANOVAs and Student-Newman-Keuls post hoc tests where appropriate. Pearson product-
moment correlations and linear regressions were used to determine relationships between 
variables. Muscle fibre type composition was based on the percentage of type I, type IIa, type 
IIb, and type IId/x fibres in the individual muscles and muscle parts of the rat hindlimb as 
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reported by Delp & Duan (1996). Significance was set at P<0.05 and values are expressed as 
mean ± SEM. 
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Chapter 4 - Results 
There was no between group differences in the total hindlimb muscle/body mass ratio 
(control: 8.8 ± 0.2, BR: 8.3 ± 0.2 %, P>0.05) despite modest differences in total body mass 
(control: 442 ± 14, BR: 384 ± 8 g, P<0.05). 
 
 Effects of BR on plasma [NO3
-
] and [NO2
-
] 
Plasma  and [NO2
-
] were significantly greater in rats receiving BR when compared 
to control (Figure 1). 
 
 Effects of BR on HR, MAP, and blood [lactate] at rest and during exercise 
HR, MAP, and blood [lactate] values are presented in Table 1. Rats receiving BR had 
significantly lower exercising but not resting MAP (P=0.48) compared to control. There were no 
differences in resting blood [lactate]. Exercising blood [lactate] was lower in the BR group 
compared to control. 
 
 Effects of BR on skeletal muscle BF and VC at rest and during exercise 
There were no differences in total resting hindlimb BF (control: 16 ± 2, BR: 20 ± 4 ml · 
min-1 · 100 g-1, P=0.30) or VC (control: 0.12 ± 0.01, BR: 0.15 ± 0.02 ml · min-1 · 100 g-1 · 
mmHg-1, P=0.20). There were no differences in resting BF or VC in any of the 28 individual 
hindlimb muscles or muscle parts (Table 2). Total exercising hindlimb muscle BF and VC was 
higher in BR supplemented rats compared to control (Figure 2). Specifically, BR resulted in 
greater BF in 17, and VC in 21, of the 28 individual hindlimb muscles or muscle parts compared 
to control (Table 3). All individual muscles and muscle parts demonstrating greater BF are 
comprised of ≥66% type IIb + d/x muscle fibers whereas VC was higher in muscles and muscle 
parts ranging from 14-100% type IIb + d/x muscle fibers. Relative differences in BF and VC 
with BR (i.e. %  BF and VC; respectively) were significantly positively correlated with the 
percentage of type IIb + d/x muscle fibres in the individual hindlimb muscles and muscle parts 
13 
 
(Figure 3). Figure 4 illustrates the marked differences in %  BF and VC for the extremes of 
muscle fiber type composition (i.e., all muscles composed of 100% and ≤20% type IIb + d/x 
muscle fibers) of the individual muscles and muscle parts of the hindlimb. 
 
 Effects of BR on renal and splanchnic BF and VC at rest and during exercise 
Renal and splanchnic BF and VC values are presented in Table 4. Renal  VC was 
significantly higher in rats receiving BR compared to control at rest (P<0.05). Liver VC was 
greater during exercise in BR supplemented rats compared to control (P<0.05). 
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Chapter 5 - Discussion 
The principal novel finding of this investigation was that 5 days of BR supplementation 
in healthy rats elevated markedly plasma [NO3
-
] and [NO2
-
] and augmented total hindlimb 
muscle BF and VC during submaximal locomotory exercise with targeted increases in the type 
IIb + d/x muscles and muscle parts.  That the changes in exercising muscle BF were evident 
despite a reduction in exercising MAP demonstrates, for the first time, that dietary NO3
-
 serves 
as a powerful controller of muscle O2 perfusion presumably following its reduction to NO2
-
 and 
NO in vivo. These results are important from several perspectives, in particular, because 
elevations in BF, and therefore O2 delivery, have the potential to raise PO2mv and hence the O2 
driving pressure across the capillary-myocyte interface (per Fick’s Law). This ultimately 
enhances oxidative function, thereby reducing glycolytic metabolism dependence, as supported 
by reduced exercising blood [lactate] (Table 2). 
 
 Effects of BR on plasma [NO3
-
], [NO2
-
] and MAP 
Crucially, both plasma [NO3
-
] and [NO2
-
] (Figure 1) rose to levels approximating what 
has been shown previously in humans following NO3
-
 supplementation (Bailey et al. 2009; 
Vanhatalo et al. 2010a; Kenjale et al. 2011; Masschelein et al. 2012). While there were no 
differences in resting MAP between groups there was a ~10 mmHg (Table 1) lower MAP during 
exercise in rats receiving BR compared to control. The exercising MAP data presented herein are 
particularly interesting given that the effects of NO3
-
 supplementation have been primarily 
studied in humans at rest.  Interestingly, rats given BR had significantly higher resting renal VC 
(Table 3) suggesting that dietary NO3
-
 reduces basal vasomotor tone and may play a 
cardioprotective role in renal vascular diseases as proposed previously (Lundberg et al. 2008; 
Tsuchiya et al. 2010; Carlström et al. 2011). 
 
 Effects of BR on exercising inter- and intra-muscular hindlimb BF and VC 
The most striking result of the present investigation was the higher exercising BF and VC 
in BR rats compared to control. Recent studies performed in humans have shown an apparent 
increase in skeletal muscle blood volume estimated using near-infrared spectroscopy following 
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NO3
-
 or NO2
-
 supplementation (Cosby et al. 2003; Bailey et al. 2009; Kenjale et al. 2011; 
Masschelein et al. 2012). However, muscle blood volume is not a measurement of BF per se 
and, therefore, to our knowledge, this is the first study investigating the effects of NO3
-
 
supplementation on inter- and intra-muscular BF and VC at rest and during exercise. 
 
The augmented BF and VC in the present investigation was observed predominantly in 
fast-twitch type IIb + d/x muscles illustrating a fibre type selective effect of dietary NO3
-
 
supplementation on vascular control (Figures 3 and 4). This could be due, in part, to the lower 
PO2mv observed during contractions in muscles composed of primarily type II vs. type I fibres 
(Behnke et al. 2003; McDonough et al. 2005; Ferreira et al. 2006c). Cosby et al. (2003) 
demonstrated that NO2
-
 reduction to NO is potentiated in low O2 environments via 
deoxyhemoglobin, deoxymyoglobin, and/or xanthine oxidoreductase. As a result, the reduction 
of NO2
- 
to NO within the microvasculature of predominantly glycolytic type II muscles is likely 
amplified following NO3
-
 supplementation, thereby increasing NO-mediated vasodilation in 
those muscles. Additionally, sympathetic adrenergic vasoconstriction occurs to a greater extent 
within more glycolytic type II compared to more oxidative type I muscles (Behnke et al. 2011) 
and the attenuation of skeletal muscle sympathetic vasoconstriction (i.e. functional 
sympatholysis) within glycolytic muscles during contractions (Thomas et al. 1994) is mediated, 
at least in part, by NO (Thomas & Victor, 1998; Dinenno & Joyner, 2004). This likely 
contributes to the observed muscle fibre type selective increases in BF and VC seen presently 
with BR during exercise but not at rest (Table 3). 
 
The lack of BF differences within the highly oxidative muscles could potentially account 
for the disparities among NO3
-
-induced improvements in short-term high intensity exercise 
(Bailey et al. 2009, Lansley et al. 2011) but not long duration exercise performance of highly 
trained endurance athletes (Cermak et al. 2012; Wilkerson et al. 2012). Any potential 
improvements in exercise performance following NO3
- 
supplementation may be limited to 
exercise testing protocols that recruit fast-twitch type II muscle fibres. There may also be a BF 
independent effect as supported by the faster rate and greater magnitude of muscle force 
development in mouse fast-twitch but not slow-twitch muscle following NO3
-
 supplementation 
reported recently by Hernandez et al. (2012). 
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BR resulted in substantially higher hindlimb skeletal muscle BF and VC (Figure 2) 
despite no reductions in BF or VC to renal or splanchnic organs during exercise compared to 
control (Table 3), which may indicate a central effect, where NO3
-
 elevates cardiac output (and 
hence skeletal muscle BF) via increases in stroke volume. Dietary NO3
-
 has previously been 
shown to attenuate ventricular dysfunction via improved cardiac contractility in Doxorubicin-
induced cardiomyopathy (Zhu et al. 2011). However, it seems more reasonable to suggest that 
the increases in BF seen herein result from a combination of peripheral and central components 
in which the increases in peripheral VC alleviate afterload, affording improvements in cardiac 
output and thus BF via an increase in stroke volume rather than a redistribution effect via 
vasoconstriction of the renal and splanchnic vascular beds. Therefore, the present data stand in 
stark contrast to the higher BF in the type IIb + d/x fibres of aged rats observed by Musch et al. 
(2004) given that the higher BFs in that report occurred concomitant with lower BF in slow 
twitch muscles and splanchnic organs. 
 
The elevated skeletal muscle BF with BR supplementation documented presently 
becomes particularly important when considering that elevating local O2 delivery ( ) relative 
to demand ( ) improves the /  relationship thereby increasing the O2 pressure head 
(PO2mv) for blood-myocyte O2 flux as dictated by Fick’s law of diffusion. Even if   remains 
unchanged (and it is likely that it decreases via improvement in mitochondrial or muscle 
contractile efficiency, Larsen et al. 2007; Bailey et al. 2009; Vanhatalo et al. 2010a), the ~38% 
increase in total hindlimb BF (Figure 2) would be expected to increase mean PO2mv substantially. 
Accordingly, the reduced PCr breakdown and improved exercise tolerance following BR 
reported by Jones and colleagues (Bailey et al. 2010; Vanhatalo et al. 2011) may have been 
mediated, in part, by elevated O2 driving pressures in the microvasculature which reduce PCr 
breakdown (Haseler et al. 1998; Vanhatalo et al. 2010b) and speed PCr recovery kinetics during 
hypoxia (Haseler et al. 1999). This mechanism is consistent with the lower blood [lactate] found 
herein with the BR group during exercise but remains to be tested specifically (Table 1). 
 
QO2
VO2 QO2 VO2
VO2
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 Experimental considerations and future directions 
A major strength of the present investigation lies in the techniques used to measure inter- 
and intra-muscular BF and VC that, due to technical and ethical limitations, are unavailable in 
humans. In this regard, the measurements of BF and VC heterogeneity across the spectrum of 
varying muscle fibre type composition presented herein provide a unique perspective as regards 
the effects of dietary NO3
-
 on skeletal muscle vascular control.  This, in combination with the 
ability to measure both whole-body exercise performance (Copp et al. 2010a) and skeletal 
muscle microvascular function (e.g., PO2mv, Behnke et al. 2003), identifies the rat as a valuable 
research tool for future studies examining the mechanistic bases of the beneficial effects of 
dietary NO3
-
 supplementation in humans.  These data have significant clinical implications for a 
host of disease conditions associated with reduced NO bioavailability and concomitant vascular 
and metabolic dysfunction, which culminates typically in compromised exercise tolerance (e.g., 
chronic heart failure; reviewed by Poole et al. 2012). A prime example illustrating the potential 
clinical benefits of BR has already been demonstrated by Kenjale et al. (2011) who showed an 
~18% increase in peak walk time and time to claudication in peripheral artery disease patients 
following a single dose of BR. 
 
The differences in total body mass between groups cannot account for the greater 
exercising blood flows in BR rats given: 1) the hindlimb mass/body mass ratios were not 
different between groups and blood flows were normalized to muscle mass, 2) data from other 
laboratories (Armstrong et al. 1985) as well as a comparison between the present control data 
and previous data from our laboratory (Copp et al. 2010b) indicate that varying body masses 
elicit similar BF values at matched treadmill speeds, 3) subsets of body mass-matched control (n 
= 5, 405 ± 8 g) and BR (n = 5, 398 ± 8, P=0.52) rats from the present investigation confirm that 
BR results in significantly higher muscle BF versus control (control: 94 ± 13, BR: 155 ± 13 ml · 
min
-1
 · 100g
-1
, P=0.01). 
 
 Conclusions 
This study is the first to investigate the effects of dietary NO3
-
 supplementation on total, 
inter-, and intra-muscular hindlimb BF and VC both at rest and during submaximal locomotory 
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exercise. In healthy rats BR supplementation for 5 days elicited marked elevations of plasma 
[NO3
-
] and [NO2
-
] and lower exercising MAP compared to control.  Moreover, BR resulted in a 
higher total hindlimb muscle BF and VC with targeted increases in the muscles and muscle parts 
comprised of principally type II + d/x muscle fibres. These data provide compelling that dietary 
NO3
-
 increases muscle O2 delivery in a fibre-type dependent manner following its reduction to 
NO2
-
 and NO in vivo. This investigation offers novel insight into the role of NO3
-
 in vascular 
control and provides a mechanistic linkage between elevated plasma [NO3
-
] and augmented 
metabolic control found in humans during exercise (Bailey et al. 2009; Bailey et al. 2010; Larsen 
et al. 2010; Kenjale et al. 2011; Vanhatalo et al. 2011).  
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Table 1. Effects of 5 days of BR supplementation on HR, MAP, and blood [lactate] at rest 
and during exercise. 
  
      HR (bpm)    MAP (mmHg)  Blood [lactate] (mM)  
 
Control      BR Control    BR Control    BR 
Rest   405 ± 8  409 ± 13 138 ± 3 132 ± 7 0.9 ± 0.1 0.7 ± 0.1 
Exercise   525 ± 9 †  521 ± 6 † 137 ± 3 127 ± 4* 2.6 ± 0.3† 1.9 ± 0.2*† 
Data are mean ± SEM. *P<0.05 vs. control, †P<0.01 vs. rest. 
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Table 2. Effects of BR supplementation on resting hindlimb muscle BF (ml · min-1 · 100 g-
1) and VC (ml · min-1 · 100 g-1 · mmHg-1). 
 BF  VC 
 
Control BR  Control BR 
Ankle extensors      
Soleus (9%) 84 ± 15 102 ± 25  0.62 ± 0.11 0.75 ± 0.18 
Plantaris (80%) 15 ± 2 10 ± 1  0.11 ± 0.01 0.08 ± 0.01 
Gastrocnemius, red (14%) 42 ± 6 50 ± 15  0.31 ± 0.05 0.37 ± 0.10 
Gastrocnemius, white (100%) 14 ± 2 10 ± 2  0.10 ± 0.02 0.08 ± 0.01 
Gastrocnemius, mixed (91%) 14 ± 2 15 ± 3  0.10 ± 0.02 0.11 ± 0.02 
Tibialis posterior (73%) 17 ± 2 15 ± 4  0.12 ± 0.01 0.11 ± 0.02 
Flexor digitorum longus (68%) 21 ± 3   10 ± 2  0.15 ± 0.02  0.07 ± 0.01 
Flexor halicus longus (71%) 13 ± 2 10 ± 1  0.09 ± 0.01 0.07 ± 0.01 
      
Ankle flexors      
Tibialis anterior, red (63%) 19 ± 3 19 ± 8  0.14 ± 0.02 0.13 ± 0.05 
Tibialis anterior, white (80%) 19 ± 2 16 ± 3  0.14 ± 0.02 0.12 ± 0.02 
Extensor digitorum longus (76%) 16 ± 2 14 ± 3  0.12 ± 0.01 0.10 ± 0.02 
Peroneals (67%) 17 ± 3 18 ± 3  0.12 ± 0.02 0.13 ± 0.02 
      
Knee extensors      
Vastus intermedius (4%) 43 ± 8 87 ± 18  0.32 ± 0.06 0.64 ± 0.26 
Vastus medialis (82%) 14 ± 2 22 ± 7  0.10 ± 0.01 0.16 ± 0.05 
Vastus lateralis, red (35%) 39 ± 6 78 ± 23  0.28 ± 0.04 0.57 ± 0.16 
Vastus lateralis, white (100%) 15 ± 2 13 ± 2  0.11 ± 0.01 0.10 ± 0.01 
Vastus lateralis, mixed (89%) 16 ± 1 26 ± 7  0.12 ± 0.01 0.19 ± 0.05 
Rectus femoris, red (66%) 22 ± 4 27 ± 11  0.16 ± 0.03 0.19 ± 0.07 
Rectus femoris, white (100%) 15 ± 2 15 ± 4  0.11 ± 0.01 0.11 ± 0.02 
      
Knee flexors      
Biceps femoris anterior (100%) 10 ± 1 10 ± 1  0.07 ± 0.01 0.08 ± 0.01 
Biceps femoris posterior (92%) 11 ± 1 13 ± 3  0.08 ± 0.01 0.10 ± 0.02 
Semitendinosus (83%) 12 ± 2 16 ± 4  0.08 ± 0.01 0.12 ± 0.03 
Semimembranosus, red (72%) 15 ± 2 24 ± 7  0.11 ± 0.02 0.18 ± 0.05 
Semimembranosus, white (100%) 13 ± 2 11 ± 2  0.09 ± 0.01 0.08 ± 0.01 
      
Thigh adductors      
Adductor longus (5%) 115 ± 7 136 ± 12  0.84 ± 0.06 1.06 ± 0.12 
Adductor magnus & brevis (89%) 15 ± 3 21 ± 5  0.12 ± 0.02 0.15 ± 0.04 
Gracilis (77%) 16 ± 2 19 ± 3  0.11 ± 0.02 0.14 ± 0.02 
Pectineus (69%) 17 ± 2 24 ± 6  0.12 ± 0.01 0.18 ± 0.04 
      
Data are mean ± SEM. Values in parentheses indicate  % type IIb + d/x according to Delp & 
Duan (1996). Control; n=11, BR; n=8. *P<0.05 vs. control. 
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Table 3. Effects of BR supplementation on exercising hindlimb muscle BF (ml · min-1 · 100 
g-1) and VC (ml · min-1 · 100 g-1 · mmHg-1).  
 BF  VC 
 
Control BR  Control BR 
Ankle extensors      
Soleus (9%) 296  ± 42 312 ± 33  2.14 ± 0.30  2.43 ± 0.23 
Plantaris (80%) 207 ± 15 247 ± 15*  1.50 ± 0.10  1.94 ± 0.10* 
Gastrocnemius, red (14%) 452 ± 44 500 ± 39  3.27 ± 0.98   3.93 ± 0.29* 
Gastrocnemius, white (100%) 42 ± 7 66 ± 11*  0.30 ± 0.05  0.51 ± 0.08* 
Gastrocnemius, mixed (91%) 149 ± 12  209 ± 17*  1.08 ± 0.08  1.64 ± 0.11* 
Tibialis posterior (73%) 118 ± 17 133 ± 17  0.85 ± 0.12   1.05 ± 0.14 
Flexor digitorum longus (68%) 99 ± 14 103 ± 15  0.71 ± 0.09 0.81 ± 0.11 
Flexor halicus longus (71%) 75 ± 10 86 ± 9  0.54 ± 0.06 0.67 ± 0.06 
      
Ankle flexors      
Tibialis anterior, red (63%) 343 ± 35 368 ± 31  2.47 ± 0.23 2.88 ± 0.20 
Tibialis anterior, white (80%) 119 ± 14 161 ± 19*  0.85 ± 0.09   1.26 ± 0.13* 
Extensor digitorum longus (76%) 55 ± 7 80 ± 10*  0.39 ± 0.05   0.62 ± 0.07* 
Peroneals (67%) 128 ± 11 166 ± 7*  0.93 ± 0.08   1.31 ± 0.06* 
      
Knee extensors      
Vastus intermedius (4%) 359 ± 39 348 ± 40  2.60 ± 0.27 2.75 ± 0.31 
Vastus medialis (82%) 114 ± 18 163 ± 30  0.82 ± 0.12 1.28 ± 0.25* 
Vastus lateralis, red (35%) 388 ± 43 449 ± 43  2.81 ± 0.28 3.56 ± 0.37* 
Vastus lateralis, white (100%) 33 ± 5 45 ± 8  0.24 ± 0.03 0.35 ± 0.06* 
Vastus lateralis, mixed (89%) 168 ± 21 227 ± 16*  1.22 ± 0.14 1.77 ± 0.14* 
Rectus femoris, red (66%) 224 ± 33 310 ± 30*  1.62 ± 0.23 2.45 ± 0.26* 
Rectus femoris, white (100%) 101 ± 13 178 ± 31*  0.72 ± 0.08 1.39 ± 0.23* 
      
Knee flexors      
Biceps femoris anterior (100%) 50 ± 8 77 ± 14*  0.36 ± 0.05 0.61 ± 0.11* 
Biceps femoris posterior (92%) 79 ± 8 130 ± 10*  0.58 ± 0.06 1.03 ± 0.08* 
Semitendinosus (83%) 56 ± 6 75 ± 12*  0.40 ± 0.04 0.58 ± 0.09* 
Semimembranosus, red (72%) 119 ± 14 174 ± 15*  0.86 ± 0.10 1.37 ± 0.11* 
Semimembranosus, white (100%) 33 ± 6 61 ± 11*  0.24 ± 0.04 0.48 ± 0.09* 
      
Thigh adductors      
Adductor longus (5%) 316 ± 38 329 ± 45  2.28 ± 0.27 2.58 ± 0.34 
Adductor magnus & brevis (89%) 83 ± 8 108 ± 15*  0.60 ± 0.05 0.85 ± 0.12* 
Gracilis (77%) 42 ± 15 57 ± 9*  0.30 ± 0.03 0.45 ± 0.07* 
Pectineus (69%) 54 ± 8 81 ± 13*  0.39 ± 0.06 0.64 ± 0.10* 
 
(Table 3 caption) 
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Data are mean ± SEM. Values in parentheses indicate % type IIb + IId/x muscle fibres according 
to Delp & Duan (1996). Control; n=11, BR; n=8. *P<0.05 vs. control. All 28 muscles and 
muscle parts of the hindlimb demonstrated elevated exercising BF and VC compared to rest 
within control and BR groups (P<0.05 for all).
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Table 4. Effects of BR supplementation on BF (ml · min
-1
 · 100 g
-1
) and VC (ml · min
-1
 · 100 g
-1
 · mmHg
-1
) to the kidneys and 
organs of the splanchnic region measured at rest and during exercise. 
 
 At rest  During exercise 
 BF  VC  BF  VC 
 Control BR  Control BR  Control BR  Control BR 
Kidney 434 ± 33 566 ± 44  3.22 ± 0.30 4.30 ± 0.25*  421 ± 42 460 ± 51  3.04 ± 0.28 3.62 ± 0.39 
Stomach 84 ± 7 91 ± 18  0.61 ± 0.06 0.66 ± 0.11  67 ± 13 59 ± 12†  0.49 ± 0.10 0.45 ± 0.08† 
Adrenals 577 ± 85 664 ± 67  4.25 ± 0.68 5.22 ± 0.69  400 ± 63 540 ± 142  2.87 ± 0.44 4.30 ± 1.19 
Spleen 339 ± 49 447 ± 104  2.47 ± 0.36 3.26 ± 0.69  62 ± 14† 108 ± 27†  0.44 ± 0.10† 0.85 ± 0.22† 
Pancreas 118 ± 10 179 ± 66  0.86 ± 0.07 1.26 ± 0.43  110 ± 15 172 ± 74  0.80 ± 0.11 1.31 ± 0.53 
Sm. intestine 313 ± 20 297 ± 36  2.30 ± 0.18 2.22 ± 0.22  240 ± 26† 255 ± 40  1.73 ± 0.18 2.00 ± 0.32 
Lg. intestine 124 ± 13 147 ± 15  0.91 ± 0.10 1.11 ± 0.08  127 ± 16 155 ± 22  0.92 ± 0.10 1.20 ± 0.15 
Liver ** 37 ± 14 32 ± 4  0.27 ± 0.10 0.25 ± 0.04  17 ± 3 34 ± 9  0.12 ± 0.02 0.26 ± 0.07* 
 
Data are mean ± SEM.  * P<0.05 vs. control; †P<0.05 vs. rest. **Indicates arterial, not portal, BF and VC.
24 
Control BR
P
la
s
m
a
 [
N
O
3
- ]
 (
M
)
0
30
60
90
120
150
180
*
P
la
s
m
a
 [
N
O
2
- ]
 (
n
M
)
0
200
400
600
800 *
Control BR
Figure 1. Effects of dietary NO3
-
 supplementation with BR on 
plasma [NO3
-
] and [NO2
-
]. * P<0.05 vs. control. 
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Figure 1. Effects of dietary NO3
-
 supplementation with BR on 
total hindlimb muscle BF and VC during submaximal 
locomotory exercise. * P<0.05 vs. control. 
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Figure 2. Relationship between the relative changes in total 
hindlimb muscle BF and VC (% Δ BF and VC, respectively) with 
dietary NO3
-
 supplementation with BR during submaximal 
locomotory exercise and the percentage of type IIb + d/x fibres 
found in the individual muscles and muscle parts of the rat 
hindlimb according to Delp & Duan (1996). 
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Figure 3. Relative changes in BF and VC (% Δ BF and VC, 
respectively)  for NO3
- 
supplemented rats compared to control during 
submaximal locomotory exercise for all hindlimb muscles and muscle 
parts comprised of 100% type IIb + d/x fibres (solid lines and 
symbols) and ≤20% type IIb + d/x fibres (dashed lines and open 
symbols) according to Delp & Duan (1996). * P<0.05 vs. control.  
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